---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014522"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:31:55.484048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028

## Summary
- Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.
- R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.
- Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.
- First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.
- Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis.

## SEC filing metadata
- accession: 0001558370-24-014522
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/0001558370-24-014522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/acrs-20241106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014522
- JSON: https://secwatch.observer/filing/0001558370-24-014522.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.